Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences is poised for significant growth with its AI-powered ECG diagnostic solutions that have the potential to transform the healthcare industry by making ECGs a more valuable tool for detecting heart disease. The company's MyoVista cloud software platform and wavECG device, which are both in the final stages of FDA approval, offer a scalable revenue opportunity through installation fees, SaaS usage fees, and marketplace fees for AI-ECG algorithms. While dilution and execution challenges pose potential risks, the company's successful 510(k) submission for the MyoVista device and upcoming commercialization of MyoVista Insights demonstrate a strong potential for future success and we maintain our buy rating with a price target of $9.20.

Bears say

HeartSciences is decreasing its expenses and raising its EPS estimates for FY26 and FY27 due to lack of visibility on commercial revenues. Additionally, the company has begun phase 1 rollout of its MyoVista Insights cloud-platform and is aiming for FDA clearance in the first half of CY2026, which may contribute to potential future revenues. However, there is still a lack of clarity on the company's commercialization strategy and revenue potential.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.